絞り込み

16603

広告

Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

著者 Thase ME , Youakim JM , Skuban A , Hobart M , Augustine C , Zhang P , McQuade RD , Carson WH , Nyilas M , Sanchez R , Eriksson H
J Clin Psychiatry.2015 Aug 4 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (23view , 0users)

Full Text Sources

Medical

Miscellaneous

To assess the efficacy, tolerability, and safety of brexpiprazole as adjunctive therapy to antidepressant treatments (ADTs) in adults with major depressive disorder (as defined by DSM-IV-TR criteria) and inadequate response to ADTs.
PMID: 26301701 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード